drugset / Trial / NCT03717194

Effect of Ertugliflozin on Cardiac Function in Diabetes

NCT03717194

Phase 3 Completed 102 enrolled Soo Lim MSD Korea Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who are not controlled with oral antidiabetic medications including DPP4 inhibitors.

Timeline

Start
2019-06-01
Primary completion
2022-12-31
Completion
2023-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ertugliflozin Unknown 5 mg